Pioneering Company

BioEclipse Therapeutics has developed a new generation of precise, targeted, immunotherapies that bring hope to patients with advanced cancer who have few treatment options due to the challenges of resistant and recurrent cancers.

Groundbreaking Technology

Solid tumors have been a challenging obstacle for all cancer therapies, including immunotherapies, reporting high failure rates. For six decades researchers have taken steps towards a cure, with remarkable progress in liquid tumors, but few inroads into solid tumors representing 90% of all cancers .

Our allogeneic technology represents a transformative approach that captures the true power of both innate and adaptive immunity to effectively treat even refractory solid tumors.

Leading-Edge Therapy

With our unique low-cost allogeneic (CRX200, IND ready) and autologous (CRX100, Phase 1b) therapies, we have demonstrated the power of an engineered immune attack against the tumor microenvironment of intractable solid cancers, using living cells programmed to assemble and instruct the diverse molecules and complex immune pathways. This technology demonstrated excellent preclinical potency against a broad range of tumor types and has been producing exciting data in the clinic.